Health & Research Goals
Metabolic Overdrive
Sobremarcha Metabólica
Triple Receptor + Mitochondrial Stack
Select a vial or the total
Primary Description
Retatrutide is the most advanced triple-receptor agonist available (GLP-1/GIP/Glucagon). MOTS-C activates AMPK and improves insulin sensitivity from within the cell. Dual approach: external receptor-level signaling + intracellular energy metabolism.
Demonstrated Effects
- Maximum fat loss via triple receptor agonism (GLP-1/GIP/glucagon)
- Prevention of metabolic plateau (MOTS-C AMPK activation)
- Superior weight loss vs dual agonist protocols
- Enhanced energy expenditure and thermogenesis
- Mitochondrial biogenesis and metabolic resilience
Proposed Mechanisms of Action
Combined Mechanism
Retatrutide is the first triple agonist compound activating GLP-1 receptors (appetite suppression, insulin secretion), GIP receptors (adipocyte lipolysis, bone metabolism, enhanced GLP-1 potentiation), and glucagon receptors (hepatic fat mobilization, basal energy expenditure increase, thermogenesis) simultaneously. Clinical data shows >24% body weight reduction over 48 weeks — superior to any single or dual agonist. MOTS-C operates at the mitochondrial level via the one-carbon folate cycle, activating AMPK to drive fatty acid β-oxidation and prevent the downregulation of metabolic rate that accompanies sustained caloric restriction.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
Maximum metabolic activation without the full triple-agonist complexity of the Beast stack. Retatrutide's unique triple GLP-1/GIP/glucagon receptor agonism delivers the most comprehensive single-compound metabolic response available, while MOTS-C's intracellular AMPK activation prevents the metabolic adaptation plateau that limits long-term weight loss outcomes.
Safety Profile
Common Side Effects
- GLP-1 class nausea, vomiting, diarrhea — titrate dose slowly over 4-8 weeks
- Thyroid C-cell tumor class warning — monitor thyroid panel
- Hypoglycemia risk if combined with insulin or sulfonylureas
- Pancreatitis risk — discontinue with severe abdominal pain
- Gallstone risk with rapid weight loss — monitor with imaging if symptomatic
Contraindications
- Personal or family history of MTC or MEN2
- Active pancreatitis
- Pregnancy
- Severe GI motility disorder
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Sobremarcha Metabólica
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.